Experts Speculate On Cause Of Neurological Damage in French FAAH Inhibitor Study
This article was originally published in SRA
Executive Summary
The French expert committee set up to look at the preclinical data on Bial's FAAH inhibitor1, BIA 10-2474, says that the adverse events that led to the death of one volunteer and the hospitalization of several others in a Phase I study of the drug could be attributable either to an action of the compound beyond FAAH inhibition or to the effects exerted by a metabolite.
You may also be interested in...
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.